Dabigatran for stroke prevention in patients with atrial fibrillation and previous stroke or transient ischemic attack: does dose matter?
Abstract
Evaluation of: Diener HC, Connolly SJ, Ezekowitz MD et al.: Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 9(12), 1157–1163 (2010). This study aimed to assess the efficacy and safety of daibgatran in two doses (110 and 150 mg) compared with warfarin in a prespecified subgroup analysis of patients with previous stroke or transient ischemic attack in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. There were nonsignificant risk reductions for the primary outcome (stroke and systemic embolism) for both doses of dabigatran compared with warfarin in this subgroup of patients. However, the 110-mg dose of dabigatran provided significantly greater reductions of mortality and higher net clinical benefit compared with warfarin. This was not seen in the 150-mg dose. The bleeding complication rates of this subgroup were consistent with the main RE-LY trial. In the warfarin group, patients with previous history of stroke or transient ischemic attack developed more intracranial bleeding than patients without this history, but this was not the case in dabigatran treatment groups.
Bibliography
- 1 Diener HC, Connolly SJ, Ezekowitz MD et al.: Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol.9(12),1157–1163 (2010).
- 2 Freeman JV, Zhu RP, Owens DK et al.: Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann. Intern. Med.154(1),1–11 (2011).
- 3 Roger VL, Go AS, Lloyd-Jones DM et al.: Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation123(4),E18–E209 (2010).
- 4 Fuster V, Rydén LE, Cannom DS et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation114(7),E257–E354 (2006).
- 5 Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.146(12),857–867 (2007).
- 6 Birman-Deych E, Radford MJ, Nilasena DS et al.: Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke37(4),1070–1074 (2006).
- 7 Fang MC, Go AS, Chang Y et al.: Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes3(6),624–631 (2010).
- 8 Reynolds MW, Fahrbach K, Hauch O et al.: Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest126(6),1938–1945 (2004).
- 9 Gage BF: Can we rely on RE-LY? N. Engl. J. Med.361(12),1200–1202 (2009).
- 10 Connolly SJ, Ezekowitz MD, Yusuf S et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361(12),1139–1151 (2009).
- 11 Schulman S, Kearon C, Kakkar AK et al.: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med.361(24),2342–2352 (2009).
- 101 Pradaxa (dabigatran etexilate) information homepage www.pradaxapro.com (Accessed 2 January 2011)
